ADC Therapeutics SA
For the period ended Mar 13, 2024. Filed Mar 13, 2024.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Mar 13, 2024 · Filed Mar 13, 2024
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · ZYNLONTA
ZYNLONTA
Achieve commercial brand profitability in 2024
LOTIS-5: Complete enrollment in 2024
LOTIS-7: Additional data from the Phase 1b dose-escalation in 3L+ in mixed histologies (Part 1) in 2Q 2024 and from the dose-expansion in 2L+ DLBCL (Part 2) in 2H 2024
Investigator-initiated trial in FL: The study is being expanded to 100 patients in a multicenter clinical trial. Updates are expected at medical meetings.
Investigator-initiated trial in MZL: The study is designed to enroll 50 patients in a multicenter clinical trial. A futility analysis is expected to be conducted in 2Q 2024. Updates are expected at medical meetings.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.